Vanda Pharmaceuticals Inc. reaffirmed sales guidance for the full year 2016 and provided sales guidance for the fourth quarter 2016 and full year 2017. For the quarter, the company expects to report total net product sales from HETLIOZ and Fanapt of approximately $38 million. For the year 2016, the company expects to report 2016 total net product sales from HETLIOZ and Fanapt of approximately $146 million, consistent with the company’s prior guidance of between $143 million and $153 million. For the full year 2017, the company expects net product sales from both HETLIOZ and Fanapt of between $165 million and $175 million.